Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for ADC118 Tablets
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for ADC118 Tablets
Filed with SSE · Stock code 688488 · · 3 pages · Chinese
Release
Jiangsu Aidea Pharmaceutical Group Co., Ltd. on 6ix
Story so far
- Announcement on Signing the Supplementary Agreement to Conditional Stock Subscription Contract with a Specific Investor and Related Party Transaction
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Announcement on Failure to Satisfy Exercise Conditions for the 1st Exercise Period under the 2025 Stock Option Incentive Plan and Cancellation of Certain Stock Options
Earlier from Jiangsu Aidea Pharmaceutical
- Announcement on Signing the Supplementary Agreement to Conditional Stock Subscription Contract with a Specific Investor and Related Party Transaction
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Announcement on Failure to Satisfy Exercise Conditions for the 1st Exercise Period under the 2025 Stock Option Incentive Plan and Cancellation of Certain Stock Options
- Announcement on Pledge of Certain Shares Held by Persons Acting in Concert with the Actual Controller
- Announcement on Results of Shareholding Increase by the Actual Controller
Later from Jiangsu Aidea Pharmaceutical
All Jiangsu Aidea Pharmaceutical news releasesFollow Jiangsu Aidea Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Aidea Pharmaceutical